Navigation Links
Amgen to Webcast 2011 Business Review Meeting on April 21
Date:4/14/2011

THOUSAND OAKS, Calif., April 14, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that it will hold its Business Review Meeting on Thursday, April 21, 2011 at the Mandarin Oriental Hotel, 80 Columbus Circle, New York City, beginning at 8 a.m. Eastern Time. In the meeting, Kevin Sharer, chairman and CEO, Robert A. Bradway, president and COO, Roger M. Perlmutter, M.D., Ph.D., executive vice president, Research and Development, and Jonathan M. Peacock, executive vice president and CFO, will discuss the Company's strategy and long-term growth objectives, commercial performance and expectations, research and development innovation and pipeline progress, financial performance expectations and the Company's capital allocation plan.

The webcast will be available to members of the news media, investors and the general public and is expected to last approximately three hours.

The webcast of the meeting, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar.  The webcast will be archived and available for replay at least 30 days after the event.

About Amgen

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... 2017 Halo Labs announces the launch of ... system called the Horizon at PEGS 2017 in ... system analyzes sub visible particulate matter in biopharmaceutical samples ... as early as candidate selection and pre-formulation. ... research organization Elion Labs for system validation. ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol ... is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex ... in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his retirement earlier this ... The former overall number one pick in the 2001 NFL Draft, to the Atlanta ... record for the most career rushing yards by a quarterback (6,109) and the most ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner ... Education Research Award. The award honors scholars exemplary in their capacity to communicate ... who has demonstrated the capacity to deepen the public’s understanding and appreciation of ...
(Date:4/24/2017)... ... April 24, 2017 , ... Sean Fay is the undisputed ... Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold more than 100 ... in the last 25 years. , Now, due to changes in the broadcast media ...
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class designers ... to bring their novel lifesaving device for the everyday use of parents worldwide. ... specially designed to read a child’s vital signs, and detect unusual symptoms or ...
Breaking Medicine News(10 mins):